Mediastinal Grey Zone Lymphoma From the LYSA

Hospices Civils de Lyon99 enrolled

Overview

Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Mediastinal Grey Zone Lymphoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * cases with an intermediate morphology and phenotype between CHL and PMBCL were included after central pathological review Exclusion Criteria: * Cases of CHL with partial CD20 expression or low expression in tumoral cells were excluded and considered as CD20-positive CHL * Exclusion of sequential form patients (with a diagnostic biopsy of PMBCL and a relapse biopsy of CHL or vise-versa) as they represent a biases for statistical analysis.

Locations (1)

Centre hospitalier Lyon sud

Pierre-Bénite, Auvergne-Rhône-Alpes, France

Outcomes

Primary Outcomes

EFS in the global population of GZL

Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause.

Time frame: EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.